




The relative strengths and weaknesses of Immix Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immix Biopharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 130% points. The greatest weakness of Immix Biopharma Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 171% points.

The company's Economic Capital Ratio, given in the ranking table, is 276%, being 0.68% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	18,186
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	202
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-6.5
Other Expenses	6.0
Other Liabilities	0
Other Net Income	-23,026
Other Revenues	0
Property and Equipment	5.7
Research and Development	127
Selling, General and Administrative Expense	1,225

Output Variable	Value in 1000 USD
Assets	18,192
Liabilities	202
Expenses	1,358
Revenues	0
Stockholders Equity	17,990
Net Income	-24,384
Comprehensive Net Income	-24,387
BaseVar	21,392
ECR before LimitedLiability	161%
Economic Capital Ratio	276%